Last updated: September 8, 2026
Eptinezumab-jjmr, marketed as Vyepti by Lundbeck, has developed into a growing preventive migraine franchise with a differentiated intravenous delivery model. U.S. sales growth has been driven by quarterly dosing, rapid onset, specialist adoption, and expansion into patients who have inadequate responses to oral preventives or other CGRP therapies. The main commercial constraints are infusion-center logistics, payer restrictions, competition from injectable CGRP antibodies and oral gepants, and the long-term risk of biosimilar competition after regulatory and patent protection declines.
Lundbeck’s reported Vyepti revenue increased from approximately DKK 1.4 billion in 2022 to DKK 1.8 billion in 2023 and approximately DKK 2.3 billion in 2024, based on company annual-report disclosures. Vyepti remains smaller than Lundbeck’s largest psychiatric products but is one of the company’s principal growth assets. [1-3]
What is eptinezumab-jjmr and how is Vyepti used?
Eptinezumab-jjmr is a humanized monoclonal antibody targeting calcitonin gene-related peptide, or CGRP. It is administered by intravenous infusion every three months for the preventive treatment of migraine in adults. The FDA approved Vyepti on Feb. 21, 2020, under Biologics License Application No. 761119. [4]
Product profile
| Attribute |
Eptinezumab-jjmr |
| Brand |
Vyepti |
| Sponsor and commercial holder |
Lundbeck |
| Active substance |
Eptinezumab |
| Modality |
Humanized monoclonal antibody |
| Target |
CGRP |
| FDA indication |
Preventive treatment of migraine in adults |
| Administration |
Intravenous infusion every three months |
| Initial FDA approval |
Feb. 21, 2020 |
| BLA |
761119 |
| Standard U.S. doses |
100 mg and 300 mg |
| Primary commercial differentiator |
Quarterly IV administration and rapid systemic exposure |
The FDA label includes both 100-mg and 300-mg doses. The 300-mg dose may provide additional benefit for some patients, although the commercial mix depends on physician selection, payer policy, and patient response. [4]
How has Vyepti revenue developed?
Vyepti’s financial trajectory has been positive since the product began commercial sales in 2020. The launch occurred during the COVID-19 pandemic, which limited infusion-center access and reduced routine specialist visits. Revenue growth accelerated as neurology practices resumed normal operations and Lundbeck expanded the product’s commercial reach.
Reported and estimated revenue trajectory
| Fiscal year |
Vyepti revenue |
Approximate growth |
Commercial context |
| 2020 |
Initial launch year |
Not comparable |
U.S. launch occurred during the pandemic |
| 2021 |
Approximately DKK 0.8 billion |
Strong growth from launch base |
Infusion access and physician adoption expanded |
| 2022 |
Approximately DKK 1.4 billion |
Approximately 70% |
Broader neurologist adoption and international rollout |
| 2023 |
Approximately DKK 1.8 billion |
Approximately 30% |
Increased U.S. penetration and recurring quarterly use |
| 2024 |
Approximately DKK 2.3 billion |
Approximately 25% |
Continued growth, with a larger installed patient base |
Sources: Lundbeck annual reports and financial releases. [1-3]
Reported figures can differ depending on whether Lundbeck presents product sales in Danish kroner, constant exchange rates, or regional reporting categories. The overall direction is clear: Vyepti has moved from launch-stage revenue to a multibillion-kroner annual product.
What is driving the financial growth?
Vyepti’s growth depends on several commercial factors.
First, quarterly dosing provides a recurring treatment cycle and reduces the daily adherence burden associated with oral preventive drugs. The dosing schedule also differentiates Vyepti from monthly subcutaneous CGRP antibodies.
Second, intravenous delivery can appeal to patients who prefer an administered treatment or have difficulty with self-injection. It may also be selected when physicians want treatment administration to occur in a supervised clinical setting.
Third, eptinezumab reaches peak plasma exposure immediately after infusion. The product’s rapid onset has been a central commercial message, particularly for patients with frequent or severe migraine attacks. Clinical studies have shown preventive efficacy beginning early in treatment, although real-world value depends on patient selection and continued dosing. [4-6]
Fourth, CGRP-targeting therapies have gained broader acceptance in migraine prevention. The American Headache Society has supported use of CGRP-targeting therapies as a first-line preventive option for appropriate patients, reducing the historical requirement to fail multiple older preventive drugs before receiving a CGRP therapy. [7]
How does Vyepti compare with competing CGRP migraine drugs?
Vyepti competes with three principal groups: injectable monoclonal antibodies, oral gepants, and established generic preventive therapies.
CGRP class comparison
| Product |
Company |
Modality |
Dosing |
Main competitive issue |
| Vyepti |
Lundbeck |
Anti-CGRP monoclonal antibody |
IV every three months |
Infusion infrastructure and administration cost |
| Aimovig |
Amgen/Novartis |
CGRP receptor antibody |
Monthly or quarterly subcutaneous dosing, depending on regimen |
Earlier market entry and self-administration |
| Ajovy |
Teva |
Anti-CGRP monoclonal antibody |
Monthly or quarterly subcutaneous dosing |
Flexible dosing and established payer access |
| Emgality |
Eli Lilly |
Anti-CGRP monoclonal antibody |
Monthly or quarterly subcutaneous dosing |
Strong migraine commercial presence |
| Qulipta |
AbbVie |
Oral gepant |
Daily oral dosing |
No infusion or injection requirement |
| Nurtec ODT |
Pfizer |
Oral gepant |
Acute and preventive use |
Dual indication and oral convenience |
| Ubrelvy |
AbbVie |
Oral gepant |
Acute treatment |
Different preventive profile but competes for CGRP-class prescribing |
Vyepti’s principal advantage is administration every three months. Its principal disadvantage is the requirement for an infusion visit. Oral gepants are more convenient for many patients, while self-injected antibodies avoid infusion-center costs.
How does Vyepti compare with Botox?
OnabotulinumtoxinA, marketed as Botox by AbbVie, is an established preventive treatment for chronic migraine. Botox is administered through multiple injections approximately every 12 weeks and has a substantial specialist infrastructure. Vyepti is also administered on a quarterly schedule but uses a single intravenous infusion rather than numerous injections.
The products compete most directly in chronic migraine, particularly among patients with high monthly headache-day burdens. Treatment choice depends on prior response, tolerability, provider preference, administration logistics, and payer rules.
What is the FDA regulatory status of eptinezumab-jjmr?
Vyepti is FDA-approved for preventive treatment of migraine in adults. It is not approved as an acute rescue treatment. The FDA label does not establish a separate indication for pediatric migraine prevention. [4]
The core regulatory protections are:
- BLA approval under the Public Health Service Act.
- Twelve years of reference-product data exclusivity for a licensed biologic under U.S. law.
- Orphan-drug exclusivity does not appear to be the principal protection for the broad adult migraine indication.
- Product labeling and postmarketing obligations remain relevant to future lifecycle changes and competing biologics.
The 12-year U.S. biologic data-exclusivity period runs from the date of first licensure, subject to statutory rules governing biosimilar applications. For Vyepti, the practical reference-product exclusivity period extends into 2032. [8]
When does Vyepti lose exclusivity?
U.S. regulatory exclusivity timeline
| Event |
Date or period |
| FDA approval |
Feb. 21, 2020 |
| Twelve-year biologic reference-product data exclusivity |
Expected to extend into February 2032 |
| Earliest practical biosimilar filing window |
Governed by the Biologics Price Competition and Innovation Act |
| Earliest possible biosimilar approval or launch |
Depends on FDA review, patent disputes, patent terms, and settlement agreements |
| Current biosimilar status |
No FDA-approved eptinezumab biosimilar publicly identified through the available regulatory record |
Regulatory exclusivity and patent exclusivity are separate. A biosimilar sponsor may begin certain preparatory activities before the end of the 12-year period, but commercial launch requires resolution of regulatory and patent barriers.
What patents protect eptinezumab and Vyepti?
Biologic patent analysis differs from small-molecule analysis. Vyepti does not have the same Orange Book listing structure used for many conventional drugs. Biologic reference products are tracked primarily through the FDA Purple Book, while patent disputes may involve composition-of-matter, antibody-sequence, epitope, formulation, manufacturing, and method-of-use claims.
Patent categories likely relevant to Vyepti
| Patent category |
Commercial relevance |
| Antibody composition |
Protects eptinezumab molecules, sequences, or related antibody variants |
| Target-binding claims |
Covers antibodies binding specified CGRP epitopes or regions |
| Formulation claims |
May cover concentration, stabilizers, pH, aggregation control, or storage |
| Manufacturing claims |
Can raise process-development and comparability barriers |
| Method-of-use claims |
May cover migraine prevention, dosing schedules, or patient populations |
| Device or administration claims |
May protect infusion presentation or delivery configurations |
Lundbeck acquired Alder BioPharmaceuticals for approximately $1.95 billion in 2019, giving Lundbeck control of eptinezumab and its associated development and intellectual-property assets. [9] The commercial value of the estate depends on claim scope, prosecution history, validity, enforceability, terminal disclaimers, patent-term adjustment, and jurisdiction.
No publicly established Vyepti patent number or expiry table should be treated as complete without a current review of the FDA Purple Book, USPTO records, international registers, and litigation databases. Patent expiry is not necessarily identical to the 2032 biologic data-exclusivity date.
What is the Orange Book status of Vyepti?
Vyepti is a biologic, so the Orange Book is not the primary source for its reference-product exclusivity or biosimilar patent information. The FDA Purple Book is the relevant biologics database. Orange Book-style assumptions about listed patents, abbreviated new drug applications, and Paragraph IV certifications do not directly apply to a biosimilar version of eptinezumab.
Are there Paragraph IV challenges to Vyepti?
A conventional Paragraph IV generic challenge is not the normal pathway for eptinezumab because Vyepti is licensed as a biologic. A competing sponsor would generally pursue a biosimilar application under section 351(k) of the Public Health Service Act rather than an abbreviated new drug application under section 505(j) of the Federal Food, Drug, and Cosmetic Act.
No widely reported eptinezumab biosimilar litigation or settlement has established a current market-entry date. Future disputes could involve the Biologics Price Competition and Innovation Act patent dance, infringement actions, patent validity, and interchangeability claims.
Which companies are challenging Vyepti commercially?
The main competitive pressure comes from companies selling alternative CGRP therapies rather than from a known eptinezumab biosimilar.
Principal competitors
- AbbVie, through Qulipta, Nurtec ODT, and Botox.
- Eli Lilly, through Emgality.
- Teva, through Ajovy.
- Amgen and Novartis, through Aimovig.
- Pfizer, through its migraine portfolio and commercial participation in Nurtec ODT.
Competition is intensifying because migraine prevention is shifting toward targeted therapies. Payers can use preferred-product arrangements, prior authorization, step therapy, and site-of-care restrictions to limit Vyepti uptake.
What generic or biosimilar launch risks exist?
The near-term risk is commercial substitution, not traditional generic erosion. Oral gepants can capture patients who would otherwise receive injectable or infused CGRP antibodies. Self-injected antibodies can also displace Vyepti when insurers prioritize lower administration costs.
The medium-term risk is biosimilar development. Eptinezumab is a complex antibody, so a biosimilar sponsor would need to establish analytical similarity, pharmacokinetic similarity, immunogenicity comparability, and clinical or confirmatory evidence under the FDA’s evolving framework. Manufacturing capability and reference-product access raise the entry cost.
The strongest barriers are likely to be:
- Complex antibody manufacturing and analytical characterization.
- Infusion-site economics and contracting.
- Patent claims covering the antibody, formulations, or use.
- The limited number of potential high-volume indications.
- Reimbursement uncertainty after launch.
What is the revenue exposure for Lundbeck?
Vyepti’s revenue is strategically important because it is a growing specialty product in a portfolio that includes mature and heavily competed products. The product’s increasing sales provide Lundbeck with exposure to the expanding migraine-prevention market and reduce reliance on older therapies.
Revenue risk is concentrated in the United States, where CGRP prescribing and reimbursement decisions have the greatest impact. Key variables include:
- Net price after rebates and discounts.
- The proportion of patients receiving 100 mg versus 300 mg.
- Buy-and-bill reimbursement for infusion administration.
- Commercial and Medicare coverage.
- Conversion from other CGRP therapies.
- Persistence over repeated quarterly doses.
- Expansion into additional international markets.
Vyepti’s sales trajectory remains growth-oriented, but the rate should moderate as the product matures and competing CGRP therapies become more interchangeable in clinical practice.
How strong is the Vyepti patent estate?
The Vyepti protection position is commercially meaningful but cannot be assessed from biologic exclusivity alone. The strongest potential protection would come from claims that cover the antibody itself and remain valid through the period when biosimilar sponsors can enter the market.
Patent strength should be evaluated across five dimensions:
- Whether core antibody claims cover the commercial molecule without narrow sequence limitations.
- Whether formulation claims protect the marketed product rather than a dispensable formulation parameter.
- Whether method-of-use claims remain enforceable after competing products receive overlapping indications.
- Whether manufacturing claims are difficult to design around.
- Whether claims survive validity challenges based on written description, enablement, obviousness, and double-patenting grounds.
The regulatory exclusivity period through approximately 2032 gives Lundbeck meaningful time to extend commercial penetration. The value of later patent protection depends on the actual issued claims and their expiration dates.
Key Takeaways
- Eptinezumab-jjmr is Lundbeck’s quarterly intravenous CGRP monoclonal antibody marketed as Vyepti.
- FDA approval occurred on Feb. 21, 2020, for preventive treatment of migraine in adults.
- Reported Vyepti revenue rose from approximately DKK 1.4 billion in 2022 to approximately DKK 2.3 billion in 2024.
- Vyepti competes with injectable CGRP antibodies, oral gepants, Botox, and generic migraine preventives.
- Its commercial advantages are quarterly administration, rapid exposure, and specialist-supervised delivery.
- Its main disadvantages are infusion requirements, site-of-care costs, and payer restrictions.
- The U.S. biologic reference-product exclusivity period extends into approximately 2032.
- Vyepti is evaluated through the Purple Book and biologics patent framework rather than conventional Orange Book generic procedures.
- No established eptinezumab biosimilar launch or major public biosimilar settlement has defined the current market.
- Future erosion risk will come first from competing CGRP products and later from biosimilar development and patent challenges.
FAQs About Eptinezumab-JJMR
Is eptinezumab-jjmr a biologic or a small-molecule drug?
Eptinezumab-jjmr is a biologic monoclonal antibody targeting CGRP. It is administered by intravenous infusion.
How often is Vyepti administered?
Vyepti is administered once every three months. The FDA-approved doses are 100 mg and 300 mg.
Is there a generic version of Vyepti?
No conventional generic version is expected because Vyepti is a biologic. Any follow-on product would generally be developed as a biosimilar under the 351(k) pathway.
Does Vyepti have FDA interchangeability status?
Vyepti is the reference biologic. No interchangeable eptinezumab biosimilar has been identified in the available FDA regulatory record.
What is the biggest commercial threat to Vyepti?
The leading near-term threat is substitution by oral gepants or self-injected CGRP antibodies, particularly where payers favor lower administration costs or simpler patient access.
References
- H. Lundbeck A/S. (2023). Annual report 2022. Copenhagen, Denmark: Author.
- H. Lundbeck A/S. (2024). Annual report 2023. Copenhagen, Denmark: Author.
- H. Lundbeck A/S. (2025). Annual report 2024. Copenhagen, Denmark: Author.
- U.S. Food and Drug Administration. (2020). Vyepti (eptinezumab-jjmr) prescribing information. Silver Spring, MD: Author.
- Dodick, D. W., Lipton, R. B., Ailani, J., et al. (2020). Eptinezumab for prevention of chronic migraine: A randomized phase 3 study. Cephalalgia, 40(4), 319-328.
- Lipton, R. B., Goadsby, P. J., Smith, J., et al. (2020). Efficacy and safety of eptinezumab in patients with chronic migraine. Neurology, 94(13), e1365-e1377.
- American Headache Society. (2024). Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine. Headache, 64(3), 333-341.
- U.S. Congress. (2010). Patient Protection and Affordable Care Act, section 7002: Approval pathway for biosimilar biological products. Washington, DC: Government Printing Office.
- H. Lundbeck A/S. (2019). Lundbeck completes acquisition of Alder BioPharmaceuticals. Copenhagen, Denmark: Author.
